Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1430306
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K on 10/22/25 with updated corporate info.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on October 22, 2025, reporting on other events and financial statements. The filing indicates the company's principal executive offices are located at 26 Main Street, Suite 101, Chatham, NJ 07928, with a business phone number of (862) 799-8599. The company was incorporated in Nevada and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Tonix Pharmaceuticals.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- October 22, 2025 (date) — Date of report
- 26 Main Street, Suite 101, Chatham, NJ 07928 (location) — Principal executive offices
- (862) 799-8599 (phone_number) — Registrant's telephone number
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report for Tonix Pharmaceuticals Holding Corp., detailing other events and financial statements, and providing updated corporate information.
When was this 8-K report filed?
The report was filed on October 22, 2025.
Where are Tonix Pharmaceuticals Holding Corp.'s principal executive offices located?
The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey, 07928.
What is the company's state of incorporation?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (862) 799-8599.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 13.7 · Accepted 2025-10-22 07:05:37
Filing Documents
- tnxp_8k-102225.htm (8-K) — 28KB
- ex99-1.htm (EX-99.1) — 35KB
- 0001999371-25-015796.txt ( ) — 235KB
- tnxp-20251022.xsd (EX-101.SCH) — 3KB
- tnxp-20251022_lab.xml (EX-101.LAB) — 33KB
- tnxp-20251022_pre.xml (EX-101.PRE) — 22KB
- tnxp_8k-102225_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On October 22, 2025, the Company announced that the first patient was dosed in the investigator-initiated FOCUS study at Massachusetts General Hospital ("MGH") in adult patients with arginine-vasopressin deficiency ("AVP-D"). A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On October 22, 2025, the Company announced that the first patient was dosed in the investigator-initiated FOCUS study at MGH in adult patients with AVP-D. The FOCUS study is a randomized, double-blind, placebo-controlled crossover pilot study that will evaluate the Company's single-dose investigational intranasal potentiated oxytocin product candidates at two different doses, 6 IU (TNX-2900) and 24 IU (TNX-1900), on markers of anxiety, depression, and socioemotional functioning in patients with AVP-D. An exploratory analysis will assess the effects of two weeks of the investigational product replacement on mental health outcomes. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future result
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 104 Press Release of the Company, dated October 22, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: October 22, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer